Navigation Links
Peregrine Reports Data Showing Bavituximab's Potential to Shrink Prostate Tumors
Date:9/7/2007

most commonly diagnosed cancer in men, accounting for 30 percent of all male cancers, and prostate cancer is second only to lung cancer as a leading cause of male cancer deaths. Currently, there is no cure for locally advanced or metastatic prostate cancer.

"We are delighted that bavituximab shrank resistant human prostate tumors in this study, an important new sign of its potential anti-cancer efficacy," said Steven W. King, president and CEO of Peregrine. "Preclinically, we have now shown that adding bavituximab equivalent antibodies to combination regimens significantly enhances the anti-tumor activity of cancer chemotherapy, of hormone deprivation therapy and of radiation therapy in prostate, breast, lung, brain and pancreatic cancers. The breadth of these potential applications supports many options for future clinical studies."

Bavituximab is a monoclonal antibody that binds to a phospholipid called phosphatidylserine that is normally located inside normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab is believed to help mobilize the body's immune system to destroy the blood vessels needed for tumor growth and spread. In a Phase Ib trial in advanced cancer patients to assess its safety in combination with common chemotherapy agents, bavituximab plus chemotherapy appeared to have a safety profile consistent with chemotherapy alone and showed positive signs of clinical activity, achieving objective response or disease stabilization in 50% of the evaluable patients. A protocol for a Phase II trial of bavituximab in combination with chemotherapy in patients with non-small cell lung cancer (NSCLC) is currently undergoing regulatory review in India. Bavituximab is also in clinical trials in the U.S. in patients with advanced solid tumors and in patients co-infected with HCV and HIV.

This study, entitled "Vascular Targeting Antib
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
2. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
3. Peregrine Pharmaceuticals Highlights Significant Advances in the Companys Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting
4. Data Presented at AACR Meeting Shows Peregrines Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
5. Data Presented at AACR Meeting Show Peregrines Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer
6. Data Presented at AACR Meeting Shows Peregrines Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
11. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), a ... blood purification technology to help fight deadly inflammation ... countries worldwide, today announced the appointment of Dr. ... as its Senior Vice President of Clinical Development, ... Di Russo is an accomplished pediatric ...
(Date:12/22/2014)... Apnea Sciences ( www.apneasciences.com ) announced it ... Aliso Viejo , California.  Jimmy Fallon , ... and worldwide expansion, a new facility with expanded infrastructure ... snore cure have exceeded our expectations and thus required ... in 23 countries and will be increasing to 39 ...
(Date:12/22/2014)... , Dec. 22, 2014   TRU-D SmartUVC ... no-touch UV disinfection robot, announced today that the General ... contract through November 2019.   This newly ... engage all levels of government purchasers, including Department of ... well as Homeland Security contacts purchasing solutions for the ...
Breaking Medicine Technology:CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2
... 26, 2012 /PRNewswire-Asia/ -- Clearbridge BioMedics has achieved ... in-vitro diagnostic devices and today launched its ... This is one of the world,s first commercially-available ... (CTC) from blood, using biomechanical properties. The ClearCell™ ...
... ST. LOUIS, March 26, 2012   Sigma-Aldrich ® ... named one of Europe,s Top Employers by the ... of academics, business journalists, trade associations, researchers and ... assessment and acknowledgement.  Sigma-Aldrich is one of nine ...
Cached Medicine Technology:Clearbridge BioMedics Achieves ISO 13485 Certification and Launches ClearCell (TM) System for Cancer Research Markets 2Clearbridge BioMedics Achieves ISO 13485 Certification and Launches ClearCell (TM) System for Cancer Research Markets 3CRF Institute Names Sigma-Aldrich Top Employer Europe 2012 2CRF Institute Names Sigma-Aldrich Top Employer Europe 2012 3
(Date:12/25/2014)... December 26, 2014 Recently, iFitDress.com, the popular ... women, has announced its new selection of black one-shoulder ... on sale now; they are available at discounted prices, up ... “The promotion will last for three weeks only. You know, ... Those who are interested in our new items can visit ...
(Date:12/25/2014)... BellasDress has launched its Christmas Sale, offering ... chosen their best-selling lace wedding dresses, vintage bridesmaid dresses ... , Now, BellasDress.com features popular women’s dresses, and ... prices. The business hopes everyone can have a memorable ... “All our elegant products are made with exquisite materials; ...
(Date:12/25/2014)... Miami, FL (PRWEB) December 25, 2014 When ... often find themselves in a frenzy to get rid of ... classroom. But families in Coral Gables now have the solution ... its second salon clinic location, Lice Troopers provides full spectrum ... in the Coral Gable area, including Sunset, Key Biscayne, Brickell, ...
(Date:12/25/2014)... THURSDAY, Dec. 25, 2014 (HealthDay News) -- The risk ... the holidays, so you need to be extra cautious, ... Day, we see a significant increase in patients coming ... at the Suffolk County Volunteer Firefighters Burn Center of ... celebrations should be full of joy, but if not ...
(Date:12/25/2014)... By Dennis Thompson ... -- Researchers could be closing in on a "fountain of ... improve the health of older adults, a new study suggests. ... when given a drug that targets a genetic signaling pathway ... maker Novartis report. The experimental medication, a ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Don't Let Burns Mar Your Holidays 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3
... Del., Sept. 14 The airline and pharmaceutical industries both provide ... dangerous if the risks are not properly calculated and dramatically lessened ... people who make and fly airplanes? , , ... webinar on the topic - Captain Ben Berman, senior research associate ...
... , , , ... President Obama in his speech to Congress and the nation ... the cost of medical malpractice and the defensive medicine that ... to control healthcare costs, and Medical Justice, a member based ...
... MONTEREY, Calif., Sept. 14 Mpex Pharmaceuticals, Inc. reported positive top ... novel aerosol formulation of levofloxacin delivered by an optimized Investigational eFlow ... trial, nebulized Aeroquin met the primary endpoint of reducing bacterial counts ... dosing versus placebo. , , "It is exciting ...
... , , , CHERRY ... NVLX) announces today that results from the Company,s ongoing sponsored ... and post-plant in several species of turfgrass. In the coming ... in the Southeastern United States under conditions that are most ...
... ... to announce the launch of the myESMO Professional Networking Community, an innovative online platform ... , ... 2009 -- The European Society for Medical Oncology is today pleased to ...
... , , PLANO, Texas, Sept. ... today announced that it will conduct a free webinar Wednesday, September ... an industry perspective and highlighting recent activities and trends. The webinar ... establish and evolve HIEs. The webinar will be hosted by ...
Cached Medicine News:Health News:Webinar Explores Drug Safety Lessons Pharma Can Learn from Airline Industry 2Health News:MedEncentive and Medical Justice Announce Partnership 2Health News:MedEncentive and Medical Justice Announce Partnership 3Health News:MedEncentive and Medical Justice Announce Partnership 4Health News:Mpex Reports Positive Phase II Results with Aeroquin, Delivered by PARI Pharma's eFlow Technology 2Health News:Mpex Reports Positive Phase II Results with Aeroquin, Delivered by PARI Pharma's eFlow Technology 3Health News:Nuvilex, Inc. Announces Positive Oraphyte(TM) Microplot Results 2Health News:Nuvilex, Inc. Announces Positive Oraphyte(TM) Microplot Results 3Health News:Nuvilex, Inc. Announces Positive Oraphyte(TM) Microplot Results 4Health News:ESMO Online Innovation Helps the Oncology Community Share Knowledge and Enhance Practice 2Health News:ESMO Online Innovation Helps the Oncology Community Share Knowledge and Enhance Practice 3Health News:ESMO Online Innovation Helps the Oncology Community Share Knowledge and Enhance Practice 4Health News:Perot Systems Webinar to Provide Industry Perspective on Health Information Exchanges 2Health News:Perot Systems Webinar to Provide Industry Perspective on Health Information Exchanges 3
The Acute Care myoglobin method is an in vitro diagnostic test for the measurement of myoglobin in heparinized whole blood /plasma. Myoglobin measurements can be used as an aid in diagnosing myocardi...
... true automation and continuous random access ... assays for thyroid, anemia, cardiac, reproductive, ... are currently available, with infectious disease ... can simultaneously process 60 accessible samples ...
IRMA kit for detection of the cardiac marker Myoglobin...
... BioCheck Prolactin ELISA is intended for the ... This assay is useful in the diagnosis ... pituitary and hypothalamus. The BioCheck Prolactin Quantitative ... a solid phase enzyme-linked immunosorbent assay. The ...
Medicine Products: